Today, Genocea Biosciences Inc. (GNCA) Receives “Buy” Rating from FBR & Co

Today, Genocea Biosciences Inc. (GNCA) Receives “Buy” Rating from FBR & Co

FBR & Co reissued their buy rating on shares of Genocea Biosciences Inc. (NASDAQ:GNCA) in a research note published on Wednesday. The brokerage currently has a $17.00 price target on the stock.

A number of other analysts have also weighed in on GNCA. Zacks Investment Research lowered shares of Genocea Biosciences from a buy rating to a hold rating in a research note on Wednesday, July 6th. Needham & Company LLC reaffirmed a buy rating and issued a $15.00 price objective on shares of Genocea Biosciences in a research note on Thursday, September 29th. Finally, Piper Jaffray Cos. lowered their price objective on shares of Genocea Biosciences from $9.00 to $12.00 and set an overweight rating for the company in a research note on Thursday, September 29th. One analyst has rated the stock with a hold rating and five have given a buy rating to the company. The company presently has a consensus rating of Buy and a consensus price target of $16.96.

Shares of Genocea Biosciences (NASDAQ:GNCA) traded down 1.81% during midday trading on Wednesday, hitting $4.34. 194,379 shares of the stock were exchanged. Genocea Biosciences has a 1-year low of $2.56 and a 1-year high of $8.20. The company’s market capitalization is $122.97 million. The firm has a 50-day moving average of $5.32 and a 200-day moving average of $4.73.

Genocea Biosciences (NASDAQ:GNCA) last issued its earnings results on Thursday, August 4th. The company reported ($0.39) earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of ($0.44) by $0.05. Genocea Biosciences had a negative net margin of 5,121.17% and a negative return on equity of 47.87%. On average, equities analysts expect that Genocea Biosciences will post ($1.63) EPS for the current year.

A number of institutional investors have recently modified their holdings of the company. Schonfeld Strategic Advisors LLC acquired a new position in shares of Genocea Biosciences during the first quarter valued at $565,000. State Street Corp increased its position in shares of Genocea Biosciences by 11.9% in the first quarter. State Street Corp now owns 291,020 shares of the company’s stock valued at $2,256,000 after buying an additional 30,920 shares during the period. Franklin Resources Inc. increased its position in shares of Genocea Biosciences by 37.0% in the first quarter. Franklin Resources Inc. now owns 2,886,600 shares of the company’s stock valued at $22,342,000 after buying an additional 779,400 shares during the period. Geode Capital Management LLC increased its position in shares of Genocea Biosciences by 1.3% in the first quarter. Geode Capital Management LLC now owns 136,990 shares of the company’s stock valued at $1,060,000 after buying an additional 1,743 shares during the period. Finally, Jacobs Levy Equity Management Inc. acquired a new position in shares of Genocea Biosciences during the first quarter valued at $662,000. Institutional investors own 56.49% of the company’s stock.

About Genocea Biosciences

Related posts

Leave a Comment